http://scholars.ntou.edu.tw/handle/123456789/10275
Title: | Development of a new type of multifunctional fucoidan-based nanoparticles for anticancer drug delivery | Authors: | Lu, Kun-Ying Li, Rou Hsu, Chun-Hua Lin, Cheng-Wei Chou, Shen-Chieh Tsai, Min-Lang Mi, Fwu-Long |
Keywords: | ANTITUMOR-ACTIVITY;ENHANCED DELIVERY;BREAST-CANCER;PROTAMINE;NANOCAPSULES;ANTICOAGULANT;THERAPY;RELEASE;PEPTIDE;SULFATE | Issue Date: | 1-Jun-2017 | Publisher: | ELSEVIER SCI LTD | Journal Volume: | 165 | Start page/Pages: | 410-420 | Source: | CARBOHYD POLYM | Abstract: | Fucoidan, a sulfated marine polysaccharide, has many potential biological functions, including anticancer activity. Recently, fucoidan has been reported to target P-selectin expressed on metastatic cancer cells. Increasing research attention has been devoted to the developments of fucoidan-based nanomedicine. However, the application of traditional chitosan/fucoidan nanoparticles in anticancer drug delivery may be limited due to the deprotonation of chitosan at a pH greater than 6.5. In this study, a mutlistimuli-responsive nanoparticle self-assembled by fucoidan and a cationic polypeptide (protamine) was developed, and their pH-/enzyme-responsive properties were characterized by circular dichroism (CD) spectroscopy, dynamic light scattering (DLS), and zeta potential analysis. Enzymatic digestion and acidic intracellular microenvironment (pH 4.5-5.5) in cancer cells triggered the release of an anticancer drug (doxorubicin) from the nanoparticles. The protamine/fucoidan complex nanoparticles with P-selectin mediated endocytosis, charge conversion and stimuli-tunable release properties showed an improved inhibitory effect against a metastatic breast cancer cell line (MDA-MB-231). (C) 2017 Elsevier Ltd. All rights reserved. |
URI: | http://scholars.ntou.edu.tw/handle/123456789/10275 | ISSN: | 0144-8617 | DOI: | 10.1016/j.carbpol.2017.02.065 |
Appears in Collections: | 食品科學系 03 GOOD HEALTH AND WELL-BEING 14 LIFE BELOW WATER |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.